ALS Reproducible Antibody Platform (ALS-RAP): Open Science to enable consistent data and accelerate reliable discoveries in Amyotrophic Lateral Sclerosis

ALS-RAP was created as a public-private partnership by three leading ALS charities - the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.

ALS-RAP is comprised of world experts in research antibody generation and validation, including the Structural Genomics Consortium (SGC) and its associated labs at the Montreal Neurological Institute (MNI) McGill University in Montreal (Canada), the University of Oxford (UK), and the Karolinska Institute (Sweden).

The project is open to community input: suggested targets, antibodies for validation, and reagent requests.

Details and current status of ALS-RAP target genes

For more information, or if you wish to propose new targets, please fill the details below

ALS-RAP team members